Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
2.130
+0.080 (3.90%)
At close: Aug 18, 2025, 4:00 PM
2.100
-0.030 (-1.41%)
After-hours: Aug 18, 2025, 4:28 PM EDT
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $1.37M in the quarter ending June 30, 2025, with 654.38% growth. This brings the company's revenue in the last twelve months to $7.41M, up 415.58% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$7.41M
Revenue Growth
+415.58%
P/S Ratio
0.37
Revenue / Employee
$926,715
Employees
8
Market Cap
6.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ENSC News
- 3 days ago - Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - GlobeNewsWire
- 5 days ago - Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates - Accesswire
- 18 days ago - Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback - Accesswire
- 4 weeks ago - Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse - Accesswire
- 7 weeks ago - Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 - Accesswire
- 2 months ago - Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025 - Accesswire
- 2 months ago - Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection - Accesswire
- 3 months ago - Ensysce Biosciences Reports First Quarter 2025 Financial Results - Accesswire